Here are 1-2 brief analogies for Lantheus:

• Think of them as a highly specialized pharmaceutical company, similar to a niche Eli Lilly or Novartis, but focused on advanced diagnostic imaging agents and targeted radiotherapies for heart disease and cancer.
• Imagine a focused GE Healthcare or Siemens Healthineers that provides the 'special dyes' and radioactive tracers for advanced medical scans and treatments, rather than the large imaging machines themselves.

• DEFINITY: A microbubble ultrasound enhancing agent used in ultrasound exams of the heart.
• TechneLite: A technetium generator for nuclear medicine.
• Xenon-133: Used to assess pulmonary function.
• Neurolite: An agent to identify areas of blocked or reduced blood flow in the brain due to stroke.
• Cardiolite: An injectable imaging agent used for cardiac imaging.
• Thallium-201: Used to detect cardiovascular disease.
• Gallium-67: Used to detect various infections and cancerous tumors.
• AZEDRA: A radiotherapeutic to treat adult and pediatric patients.
• Automated Bone Scan Index (ABSI): Software that calculates the disease burden of prostate cancer by quantifying hotspots on bone scans.
• Cobalt (Co 57): A non-pharmaceutical radiochemical.
• RELISTOR: A product for treating opioid-induced constipation.
• PYLARIFY: An agent for visualizing metastases in prostate cancer, including lymph nodes, bone, and soft tissue.

Lantheus (LNTH) primarily sells its diagnostic and therapeutic products to other organizations rather than directly to individuals. Based on the provided description, its major customers fall into the following categories:

• Radio pharmacies
• Distributors
• Integrated delivery networks
• Hospitals
• Clinics
• Group practices

As these are broad categories of customers and not specific named public companies, company symbols are not applicable in this context.

Major Suppliers:

• Bausch Health Companies, Inc. (BHC)
• GE Healthcare Limited (GEHC)
• Curium
• Bayer AG (BAYRY)
• CytoDyn Inc. (CYDY)
• ROTOP
• FUJIFILM (FUJIY)
• Regeneron Pharmaceuticals, Inc. (REGN)
• NanoMab Technology Limited
• POINT Biopharma US Inc.

Mary Anne Heino Executive Chairperson and Interim CEO
Mary Anne Heino serves as interim Chief Executive Officer and Executive Chairperson of Lantheus. She previously held the position of CEO from August 2015 to March 2024. Ms. Heino joined Lantheus in April 2013 as Chief Commercial Officer and was promoted to Chief Operating Officer in March 2015. With nearly 20 years of executive leadership, her background includes senior commercial and strategic leadership roles at Angelini Labopharm, Labopharm USA, and Centocor (a Johnson & Johnson company), preceded by a career in sales management at Janssen Pharmaceutica. She led Angelini Labopharm LLC and Labopharm USA as president and SVP of worldwide sales and marketing from February 2007 to March 2012. Under her leadership, Lantheus acquired Progenics in June 2020.

Robert J. Marshall Jr. Chief Financial Officer
Robert J. Marshall Jr. joined Lantheus as Chief Financial Officer and Treasurer in September 2018. He brings over 30 years of finance experience, including expertise in M&A, capital markets, and investor relations. Prior to Lantheus, Mr. Marshall spent 16 years with Zimmer Biomet Holdings, Inc., a global medical device company, where he held various senior leadership roles such as Vice President, Investor Relations, Corporate Treasurer, and Vice President.

Cheryl Ball Chief Strategy Officer and Head of Corporate Development
Cheryl Ball joined Lantheus in 2019 and serves as Chief Strategy Officer and Head of Corporate Development. Her responsibilities include leading corporate development efforts, establishing portfolio management functions, and overseeing annual strategic planning processes. Prior to Lantheus, she held leadership roles at Acorn Strategies as Vice President of Portfolio Planning and at Evidera as Senior Director of Corporate Strategy and Portfolio Management. Her earlier experience includes director roles at AstraZeneca and Quintiles, focusing on strategic assessments and market strategy initiatives.

Ludger Dinkelborg, PhD Head of Research and Development
Ludger Dinkelborg, PhD, was appointed Head of Research and Development at Lantheus, effective August 1, 2025, following the company's acquisition of Life Molecular Imaging Ltd. He previously served as CEO and Managing Director of Life Molecular Imaging and is a co-founder of the company. Dr. Dinkelborg oversees global research and development activities in oncological, neurodegenerative, and cardiovascular indications. He also held positions as Director at Piramal Imaging SA.

Amanda Morgan Chief Commercial Officer
Amanda Morgan was promoted to Chief Commercial Officer at Lantheus, effective March 25, 2024, having joined the company in November 2022 as Senior Vice President, Commercial. She possesses over 20 years of experience in the healthcare industry. Before joining Lantheus, Ms. Morgan was the Chief Revenue and Customer Officer at Acadia Pharmaceuticals, where she led the commercial organization. She also held various leadership roles with increasing responsibility at Shire Plc, including U.S. Head of Sales and U.S. Head of Patient Services, and held leadership roles at Baxter.

Key Business Risks for Lantheus Holdings, Inc.

Lantheus Holdings, Inc. faces several key risks inherent in the biotechnology and pharmaceutical industries.

1. Clinical Development and Regulatory Approval Risk for Pipeline Products: Lantheus has a significant pipeline of investigational products, including flurpiridaz F 18, 1095, LMI 1195, PYLARIFY AI, and leronlimab, an investigational humanized monoclonal antibody. The success of these products is highly dependent on favorable outcomes in clinical trials and obtaining regulatory approvals from health authorities. Failure to demonstrate efficacy and safety, delays in clinical development, or inability to secure regulatory clearance for these pipeline candidates could significantly impact the company's future growth prospects and financial performance.

2. Competition and Market Acceptance of Existing Products: The markets for Lantheus's diagnostic and therapeutic products, such as DEFINITY, TechneLite, PYLARIFY, and others, are highly competitive. The continued commercial success of these products is subject to intense competition from existing and new market entrants, pricing pressures, evolving clinical practice guidelines, and the potential for alternative therapies or technologies to emerge. A decline in market acceptance or increased competition for its key commercialized products could adversely affect the company's revenues and profitability.

3. Specialized Supply Chain and Manufacturing Risks for Radiopharmaceuticals: A substantial portion of Lantheus's product portfolio consists of radiopharmaceuticals (e.g., TechneLite, Xenon-133, Cardiolite, Thallium-201, Gallium-67, AZEDRA). These products rely on the secure and timely supply of medical isotopes and other specialized raw materials, which often have complex and geographically concentrated global supply chains. Any disruptions in the production of these isotopes, manufacturing processes, or distribution networks due to regulatory issues, operational failures, or unforeseen events could severely impact Lantheus's ability to produce and sell its radiopharmaceutical products.

Lantheus (symbol: LNTH) operates in several significant addressable markets with its key diagnostic and therapeutic products:

• PYLARIFY (prostate cancer imaging): The U.S. market potential for PSMA PET imaging, in which PYLARIFY is the number one utilized agent, may exceed $3.5 billion by the end of the decade. The global prostate cancer diagnostics market size was estimated at USD 9.72 billion in 2025 and is predicted to increase to approximately USD 18 billion by 2035, growing at a CAGR of 6.36% from 2026 to 2035. North America held the largest market share, 46%, in the global prostate cancer diagnostics market in 2025. The U.S. prostate cancer nuclear medicine diagnostics market size reached USD 119.06 million in 2023 and is projected to reach approximately USD 289.71 million by 2033, expanding at a CAGR of 9.2%.
• DEFINITY (microbubble ultrasound enhancing agent): The global microbubbles/ultrasound contrast agents market was valued at USD 2.62 billion in 2024 and is poised to grow to USD 3.93 billion by 2033, with a CAGR of 4.6% during the forecast period (2026–2033). The overall global ultrasound-enhancing agents market was valued at US$ 756.61 million in 2023 and is projected to reach US$ 2,511.52 million by 2031, with an estimated CAGR of 16.2%. North America holds the largest market share in the ultrasound contrast agents market, accounting for approximately 35% of the global market. The global high-density ultrasound contrast agent market size was valued at USD 157 million in 2024 and is projected to grow to USD 471 million by 2032, exhibiting a CAGR of 17.2%.
• TechneLite (technetium generator): The Technetium-99m market size is projected to reach US$ 4.54 billion in 2024 and US$ 6.03 billion by 2031, registering a CAGR of 4.2% during 2025–2031. The global Technetium 99m market size was valued at USD 6,482.4 million in 2025 and is expected to reach USD 10,122.5 million by 2034, growing at a CAGR of 5.02%. Another estimate places the global Technetium-99m (Tc-99m) market at USD 5.6 billion in 2024, projected to reach USD 8.1 billion by 2030, reflecting a CAGR of 6.3%. North America maintained a 37.67% share of the technetium-99m market size in 2024.
• AZEDRA (radiotherapeutic for pheochromocytoma and paraganglioma):AZEDRA was discontinued in 2023 due to insufficient commercial demand, with manufacturing continuing only until Q1 2024. The pheochromocytomas and paragangliomas market size in the 7MM (7 Major Markets: US, EU4, UK, and Japan) is expected to grow from USD 314 million in 2025 to USD 662 million in 2034. The global paraganglioma market size was valued at USD 304.18 million in 2024 and is projected to grow from USD 316.71 million in 2025 to USD 437.46 million by 2033, with a CAGR of 4.12%. North America is the most significant global paraganglioma market shareholder.
• flurpiridaz F 18 (to assess blood flow to the heart): The Flurpiridaz market is projected to grow from USD 546.9 million in 2025 to USD 1202.6 million by 2035, at a CAGR of 8.2%. From 2020 to 2024, the flurpiridaz market expanded from USD 353.8 million to USD 508.6 million. The market is expected to record a rapid expansion trajectory with a compound annual growth rate (CAGR) of 12.1%. GE HealthCare holds a dominant global position (83.5% in 2024) in the flurpiridaz market.
• NEURACEQ (Alzheimer's radiodiagnostic): Lantheus estimates the Alzheimer's radiodiagnostic market could be a $1.5 billion total addressable market by the end of the decade and $2.5 billion by the mid-2030s. Neuraceq exited 2025 as the second largest and fastest growing commercially approved amyloid PET imaging agent utilized in the U.S.

Lantheus Holdings, Inc. (LNTH) is expected to drive future revenue growth over the next 2-3 years through a combination of new product launches, significant expansion in the Alzheimer's diagnostic market, and the continued performance of its core products.

Here are 3-5 expected drivers of future revenue growth:

1. Launch and Expansion of New PET Radiodiagnostics: Lantheus anticipates multiple FDA approvals and commercial launches of new products within its radiodiagnostics pipeline. Key among these are OCTEVY, a PET radiodiagnostic for GEP-NET imaging with a PDUFA date of March 29, 2026, and a new formulation of PYLARIFY, aimed at increasing batch size and efficiency, with a PDUFA date of March 6, 2026. These launches are expected to provide meaningful revenue contributions starting in 2027. Additionally, royalties from flurpiridaz F 18, an FDA-approved PET myocardial perfusion imaging agent for coronary artery disease that became available in early 2025, will contribute to revenue.
2. Growth in the Alzheimer's Disease PET Imaging Market with Neuraceq: The acquisition of Neuraceq, an approved radiodiagnostic for Alzheimer's disease, positions Lantheus for significant growth in the expanding Alzheimer's disease PET imaging market. The company projects triple-digit inorganic growth for Neuraceq in 2026, driven by the increasing adoption of disease-modifying therapies for Alzheimer's and expanded diagnostic guidelines.
3. Continued Performance and New Formulation of PYLARIFY: Despite facing intensified competition and some pricing pressure, PYLARIFY remains a leading PSMA PET imaging agent for prostate cancer and a major revenue contributor. While net revenue for PYLARIFY is expected to decline 8-10% in 2026 due to these dynamics, increased volume is still anticipated. The planned transition to a new, more efficient PYLARIFY formulation from late 2026 onwards is expected to enhance patient access, supply resilience, and production efficiency, supporting future growth and market leadership.
4. Steady Growth of DEFINITY: DEFINITY, Lantheus's microbubble ultrasound enhancing agent for heart exams, is a stable product in the company's portfolio. It is projected to continue generating revenue growth in the low to mid-single digits over the next few years.

Share Repurchases

• Lantheus' board of directors authorized a program in November 2024 to repurchase up to $250 million of its common stock over the next twelve months.
• In August 2025, this program was superseded by a new authorization to repurchase up to $400 million of common stock through December 31, 2027.
• The company repurchased $100 million of common stock in the third quarter of 2025 and another $100 million in the fourth quarter of 2025.

Share Issuance

• Lantheus' shares outstanding increased from 70,905 shares (in thousands) as of December 31, 2024, to 71,607 shares (in thousands) as of March 31, 2025.

Outbound Investments

• In 2025, Lantheus completed the acquisition of Evergreen Theragnostics, Inc., costing $276.4 million, which added OCTEVY and radioligand therapy manufacturing infrastructure.
• In 2025, the company also completed the acquisition of Life Molecular Imaging, for approximately $355.2 million to $352.9 million, bringing Neuraceq and an expanded commercial footprint.
• Lantheus divested its legacy SPECT business, effective January 1, 2026, to SHINE Technologies LLC, to strategically focus on innovative PET radiodiagnostics.

Capital Expenditures

• Capital expenditures totaled $27.301 million for the full year 2025, a decrease from $35.256 million in 2024.
• In the fourth quarter of 2025, capital expenditures were $8.8 million, which was $7.6 million less than the prior year's fourth quarter.
• For 2026, Lantheus plans to invest in commercialization infrastructure, sales and marketing for new products like the new PSMA PET formulation and OCTEVY, and R&D for phase-gated projects, prioritizing radiodiagnostics.